Tirzepatide

What it is

Tirzepatide is a synthetic peptide drug designed to activate two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIP) and the glucagon-like peptide-1 receptor (GLP-1)^{[1 –2 ]}. It is sold in the United States as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity^{[1 –2 ]}. Although it is often grouped publicly with “GLP-1 medications,” tirzepatide is pharmacologically distinct from single-receptor GLP-1 receptor agonists because it activates both GIP and GLP-1 receptors^{[1 –3 ]}.

Chemical structure

The molecule is based on the GIP sequence and contains aminoisobutyric acid substitutions at positions 2 and 13, a C-terminal amide, and a lysine-linked fatty diacid modification that increases albumin binding and extends duration of action^{[1 ]}. FDA labeling describes tirzepatide as containing a C20 fatty diacid that prolongs half-life, with an apparent elimination half-life of approximately five days, enabling once-weekly administration in approved products^{[1 ]}.

Mechanism

Tirzepatide binds and activates both GIP and GLP-1 receptors, which are targets for endogenous incretin hormones involved in post-meal glucose and energy regulation^{[1 ,3 ]}. In people with type 2 diabetes, the Mounjaro label states that tirzepatide enhances first- and second-phase insulin secretion and reduces glucagon levels in a glucose-dependent manner^{[1 ]}. The label also describes reductions in fasting and postprandial glucose, decreased food intake, reduced body weight, increased insulin sensitivity, and delayed gastric emptying — with the gastric-emptying effect largest after the first dose and diminishing over time^{[1 ]}.

Approved products

Tirzepatide was developed by Eli Lilly and advanced through the SURPASS clinical-trial program for type 2 diabetes and the SURMOUNT program for obesity and weight-related conditions^{[4 –14 ]}. FDA-approved tirzepatide products in the United States are:

• Mounjaro — approved May 13, 2022 for adults with type 2 diabetes; the April 2026 label adds pediatric patients aged 10 and older with type 2 diabetes^{[1 ,4 ]}.
• Zepbound — approved November 8, 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity^{[2 ,5 ]}; FDA expanded the labeling on December 20, 2024 to include moderate-to-severe obstructive sleep apnea in adults with obesity^{[6 ]}.

Administration

Approved tirzepatide products are administered by subcutaneous injection^{[1 –2 ]}. The FDA dosing schedules include gradual escalation to reduce gastrointestinal adverse reactions; this page does not provide dosing instructions or individualized medical guidance^{[1 –2 ]}.

Regulatory status

Tirzepatide is FDA-approved in the United States as a prescription drug in branded products. Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus^{[1 ]}. Zepbound is indicated, in combination with reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight and at least one weight-related comorbid condition, and to treat moderate-to-severe obstructive sleep apnea in adults with obesity^{[2 ]}.

Approval timeline

FDA approval dates differ by product and indication. Mounjaro’s original approval date was May 13, 2022^{[4 ]}. Zepbound was approved for chronic weight management on November 8, 2023^{[5 ]}. FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024, describing it as the first approved drug treatment option for certain patients with obstructive sleep apnea^{[6 ]}. Mounjaro labeling was updated in 2025–2026 to include pediatric patients 10 years of age and older with type 2 diabetes^{[1 ]}.

Compounding policy

Compounding status is materially different from FDA approval status. FDA announced on December 19, 2024 that it had determined the tirzepatide injection shortage was resolved after reevaluating its earlier October 2024 determination^{[7 ]}. FDA later stated that enforcement-discretion periods tied to tirzepatide’s shortage-list status had ended for 503A state-licensed pharmacies and physicians, and that the 503B enforcement-discretion period for outsourcing facilities ended March 19, 2025^{[7 ]}. As of FDA’s April 1, 2026 update, tirzepatide does not appear on FDA’s drug shortage list or on the 503B bulks list^{[7 ]}.

Under section 503A, FDA policy restricts compounding that is regularly or inordinately an essentially copied version of a commercially available drug product^{[7 ]}. FDA states that a compounded drug product may be considered essentially a copy when it has the same active ingredient in the same, similar, or easily substitutable strength and can be used by the same route of administration, unless a prescriber documents that a change produces a significant difference for an identified individual patient^{[7 ]}. Under section 503B, outsourcing facilities generally may not compound from bulk drug substances unless the substance appears on the 503B bulks list or the compounded drug is on the FDA drug shortage list at the time of compounding, distribution, and dispensing^{[7 –8 ]}.

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound these drugs from bulk substances^{[8 ]}. The proposal invited public comment through June 29, 2026 before a final determination^{[8 ]}. Regulatory status should be rechecked before publication because the public-comment process was still open as of this draft’s verification date.

Controlled-substance status

Tirzepatide is not listed in the federal controlled-substance schedules in 21 CFR Part 1308, and FDA-approved Mounjaro and Zepbound labels do not identify tirzepatide as a controlled substance^{[1 –2 ,9 ]}. International regulatory status differs by jurisdiction and indication; this page focuses on United States status. Last regulatory verification: May 5, 2026.

Research summary

Tirzepatide has a large clinical-trial evidence base for type 2 diabetes, obesity, and selected obesity-related conditions.

Type 2 diabetes — SURPASS program

In SURPASS-1, a 40-week double-blind phase 3 trial in adults with type 2 diabetes inadequately controlled with diet and exercise alone, tirzepatide monotherapy improved HbA1c and reduced body weight compared with placebo^{[10 ]}. In SURPASS-2, a 40-week trial in patients with type 2 diabetes, tirzepatide was compared with once-weekly semaglutide 1 mg and produced greater reductions in HbA1c and body weight across tested tirzepatide doses^{[11 ]}. SURPASS-4 studied patients with type 2 diabetes and increased cardiovascular risk and found greater glycemic and weight effects with tirzepatide than insulin glargine, with a cardiovascular safety assessment built into the trial design^{[12 ]}. SURPASS-5 found that tirzepatide added to titrated insulin glargine improved glycemic control compared with placebo in adults with type 2 diabetes inadequately controlled on basal insulin, with or without metformin^{[13 ]}.

Cardiovascular outcomes in type 2 diabetes

Cardiovascular outcomes were evaluated more directly in SURPASS-CVOT, an active-comparator trial published in 2025. The trial randomized 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide, a GLP-1 receptor agonist with established cardiovascular-outcomes evidence^{[14 ]}. Tirzepatide was noninferior to dulaglutide for the composite of cardiovascular death, myocardial infarction, or stroke, with a hazard ratio of 0.92 and a 95.3% confidence interval of 0.83 to 1.01; superiority was not statistically established^{[14 ]}. Mounjaro labeling as of April 2026 does not list a cardiovascular risk-reduction indication^{[1 ]}.

Chronic weight management — SURMOUNT program

For obesity, SURMOUNT-1 randomized 2,539 adults with obesity or overweight and at least one weight-related complication, excluding diabetes, to tirzepatide or placebo for 72 weeks^{[15 ]}. Mean body-weight change at week 72 was −15.0% with tirzepatide 5 mg, −19.5% with 10 mg, −20.9% with 15 mg, and −3.1% with placebo^{[15 ]}. Gastrointestinal adverse events were the most common adverse events and were usually mild to moderate, occurring mainly during dose escalation^{[15 ]}. SURMOUNT-2 studied adults with obesity and type 2 diabetes and also found greater weight reduction with tirzepatide than placebo^{[16 ]}.

Several SURMOUNT trials addressed weight maintenance and the relationship between lifestyle intervention and medication. SURMOUNT-3 randomized adults who had already achieved at least 5% weight loss during a 12-week intensive lifestyle intervention to tirzepatide or placebo for 72 additional weeks; tirzepatide produced additional mean weight reduction while placebo was associated with weight regain^{[17 ]}. SURMOUNT-4 used a randomized-withdrawal design: after a 36-week open-label tirzepatide lead-in, participants who continued tirzepatide lost additional weight during the randomized phase, while those switched to placebo regained weight^{[18 ]}. These findings support the interpretation that tirzepatide-associated weight reduction often depends on continued treatment in the studied populations, rather than a short finite course^{[18 ]}.

Obstructive sleep apnea — SURMOUNT-OSA

Zepbound’s obstructive sleep apnea indication is supported by SURMOUNT-OSA, two phase 3 randomized trials in 469 adults with moderate-to-severe obstructive sleep apnea and obesity — one trial in participants not using positive airway pressure therapy and one in participants using positive airway pressure therapy^{[19 ]}. Participants were assigned to tirzepatide or placebo for 52 weeks, and the primary endpoint was change in apnea–hypopnea index^{[19 ]}. The trials found statistically significant reductions in apnea–hypopnea index with tirzepatide compared with placebo, and FDA stated that improvement in apnea–hypopnea index was likely related to body-weight reduction^{[6 ,19 ]}.

Off-label and emerging indications

Tirzepatide has also been studied for conditions that are not currently FDA-approved tirzepatide indications. In SYNERGY-NASH, a phase 2 trial in biopsy-confirmed MASH with F2–F3 fibrosis, 190 participants were assigned to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 52 weeks^{[20 ]}. Tirzepatide was associated with higher rates of MASH resolution without worsening of fibrosis than placebo; fibrosis improvement was also reported, but this remains a phase 2 finding and has not resulted in an FDA-approved MASH indication for tirzepatide as of May 5, 2026^{[20 ]}. In SUMMIT, a randomized trial in 731 patients with heart failure with preserved ejection fraction and obesity, tirzepatide reduced the composite of cardiovascular death or worsening heart-failure event and improved Kansas City Cardiomyopathy Questionnaire clinical summary scores compared with placebo^{[21 ]}. This finding is clinically important but does not itself establish a current FDA-approved HFpEF indication for tirzepatide^{[1 –2 ,21 ]}.

Where the evidence ends

The strongest evidence for tirzepatide is for FDA-approved uses: type 2 diabetes glycemic control, chronic weight management in label-defined adults, and moderate-to-severe obstructive sleep apnea in adults with obesity^{[1 –2 ,4 –6 ,10 –19 ]}. Evidence is promising but still evolving for MASH and HFpEF with obesity, and cardiovascular superiority over dulaglutide was not demonstrated in SURPASS-CVOT^{[14 ,20 –21 ]}. Claims that tirzepatide is broadly useful for nonspecific “longevity,” cosmetic weight loss in people outside approved criteria, addiction treatment, or general metabolic optimization should not be treated as established clinical evidence as of this review date.

Public discourse

Peter Attia, MD, on The Drive, discussed GLP-1 and incretin-based drugs — including Mounjaro — with emphasis on efficacy, discontinuation, body composition, protein intake, and resistance training. The commentary is educational opinion and not product-specific prescribing guidance^{[22 ]}.

Ania M. Jastreboff, MD, PhD, a Yale endocrinologist and obesity-medicine researcher, framed obesity as a biologically mediated chronic disease and discussed nutrient-stimulated hormone-based medications such as tirzepatide and semaglutide^{[23 ]}.

Sally Seymour, MD, an FDA Center for Drug Evaluation and Research official, characterized the Zepbound obstructive sleep apnea approval as a regulatory milestone for a defined patient population: adults with obesity and moderate-to-severe OSA^{[6 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

FDA-approved tirzepatide products carry a boxed warning for thyroid C-cell tumors observed in rats; the human relevance is unknown^{[1 –2 ]}. Mounjaro and Zepbound are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2^{[1 –2 ]}. They are also contraindicated in patients with known serious hypersensitivity to tirzepatide or any product excipients^{[1 –2 ]}.

Common adverse reactions

The most common adverse reactions are gastrointestinal. Mounjaro’s label lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain among adverse reactions reported in at least 5% of treated patients^{[1 ]}. Zepbound’s label lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease among common adverse reactions^{[2 ]}. In the pivotal obesity trial, adverse events leading to discontinuation occurred more often in tirzepatide groups than placebo, and gastrointestinal effects occurred mainly during dose escalation^{[15 ]}.

Important warnings

Important warnings include severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions, hypoglycemia when used with insulin or insulin secretagogues, diabetic retinopathy complications in patients with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation^{[1 –2 ]}. Zepbound’s February 2026 label revision removed the prior warning for suicidal behavior and ideation, but psychiatric symptoms and eating-disorder context may still be clinically relevant in obesity care and should be handled by qualified clinicians^{[2 ]}.

Drug interactions

Drug-interaction concerns are partly related to delayed gastric emptying. FDA labeling states that tirzepatide delays gastric emptying and may affect absorption of concomitantly administered oral medications^{[1 –2 ]}. The Mounjaro label also advises that females using oral contraceptives switch to a non-oral method or add a barrier method for four weeks after initiation and four weeks after each dose escalation, because tirzepatide may reduce oral contraceptive exposure^{[1 ]}.

Long-term safety

Long-term safety data are more developed than for many research peptides because tirzepatide has large phase 3 programs and multi-year outcome studies^{[10 –21 ]}. However, decades-long real-world data remain limited, especially for newer indications, pediatric type 2 diabetes, OSA, high-risk cardiovascular populations, MASH, HFpEF, and use outside FDA-approved populations^{[1 –2 ,14 ,19 –21 ]}.

Available through

FDA-approved tirzepatide is available in the United States by prescription through licensed clinicians and pharmacies dispensing approved branded products such as Mounjaro and Zepbound, when used within applicable prescribing rules and product labeling^{[1 –2 ]}.

Telehealth platform partnerships are pending verification. Provider listings will be added only after legal and editorial review confirms that the platform prescribes FDA-approved tirzepatide through licensed clinicians and dispenses through compliant pharmacy channels. ProPeptideGuide does not link to or endorse gray-market vendors, research-chemical sites, or compounded tirzepatide products marketed as copies of FDA-approved products^{[7 –8 ]}.